drugset / Trial / NCT01985893
Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
Phase 2
Withdrawn
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
OnkoDataMed GmbH · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to estimate the clinical benefit of lapatinib plus trastuzumab compared to lapatinib plus capecitabine as measured by investigator-assessed progression-free survival, tumour response and overall survival.
Timeline
- Start
- 2013-09
- Primary completion
- 2015-03
- Completion
- 2015-03
Outcome
Outcome not reported
Stopped (Enrollment): “Due to missing patient recruitment, the financial support was stopped.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |